BIO vs GMED
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 09, 2026
BIO
GMED
Investment Advisor Scores
GMED
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BIO | GMED | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 41.4938 | 16.2866 | GMED |
| PEG Ratio | 4.0063 | 1.4934 | GMED |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -0.1% | 5.9% | GMED |
| Earnings Growth | 18.7% | -26.2% | BIO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 59.7/100 | 39.1/100 | BIO |
| Profit Margin | 8.6% | 17.0% | GMED |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | BUY | AVOID NEW MONEY | BIO |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BIO
MarkupPrice above SMA50, rising 50-day trend (0.6% over 20 days), RSI 58
GMED
DistributionPrice near a flattening SMA50 (slope -2.5%) with fading momentum, RSI 46
Fundamentals Snapshot
| Metric | BIO | GMED |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 39.0 | 14.1 |
| Trailing P/E | 10.3 | 18.8 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.0% |
| Gross Margin | 0.5% | 0.7% |
| Operating Margin | 0.1% | 0.2% |
| EPS | 37.64 | 4.06 |
| Dividend Yield | — | — |